Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/21509| Title: | Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. | Austin Authors: | Sasadeusz, Joe;Grigg, Andrew P ;Hughes, Peter D;Lee Lim, Seng;Lucas, Michaela;McColl, Geoff;McLachlan, Sue Anne;Peters, Marion G;Shackel, Nicholas;Slavin, Monica;Sundararajan, Vijaya;Thompson, Alexander;Doyle, Joseph;Rickard, James;De Cruz, Peter;Gish, Robert G;Visvanathan, Kumar | Affiliation: | University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia University of California, San Francisco, S357 Parnassus Avenue, San Francisco, CA 94143, USA Ingham Institute, 1 Campbell Street, Liverpool, Sydney, New South Wales 2170, Australia Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia Department of Public Health, La Trobe University, Plenty Road, Bundoora, Victoria 3086, Australia Burnet Institute, 85 Commercial Road, Melbourne, Victoria 3004, Australia The Alfred and Monash University, 85 Commercial Road, Melbourne, Victoria 3004, Australia St Vincent's Hospital, 41 Victoria Street, Fitzroy, Victoria 3065, Australia Peter Doherty Institute for Infection and Immunity, Elizabeth Street, Melbourne, Victoria 3000, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA University of Queensland Oral Health Centre, 288 Herston Road, Queensland 4006, Australia Royal Melbourne Hospital, 300 Grattan Street, Parkville, Victoria 3050, Australia University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia National University of Singapore, 21 Lower Kent Ridge Road, Singapore 119077, Singapore |
Issue Date: | Aug-2019 | Date: | 2019-06-06 | Publication information: | Clinics in liver disease 2019; 23(3): 487-492 | Abstract: | Current recommendations concerning hepatitis C virus (HBV) reactivation are limited, with nearly all guidelines focused on its occurrence in patients with hematological malignancies or some solid tumors, who are treated with immunosuppressive therapies. Few of the guidelines address reactivation in patients receiving immunosuppression with organ transplants or treatment with any of the many immunosuppressive agents in use today for the treatment of multiple different diseases, or in patients receiving the direct-acting antivirals used in the treatment of hepatitis C virus (HCV). This article covers the immunology of HBV reactivation, mechanisms of viral clearance, and recommendations for screening and prophylaxis. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/21509 | DOI: | 10.1016/j.cld.2019.04.009 | Journal: | Clinics in liver disease | PubMed URL: | 31266622 | Type: | Journal Article | Subjects: | Adaptive Hepatitis B immunology Hepatitis B virus Innate Prophylaxis Reactivation |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.